This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Here’s a Sneak Peek at a few AsiaTIDES 2019 Confirmed Speakers & Presentations

We've extended the speaker submisssion deadline until September 14

KEYNOTE SPEAKER:

The Discovery of Semaglutide – A Journey from Ala Scan to Structural Design of GLP-1 Analogues
Jesper Lau, Ph.D., Vice President, Protein & Peptide Chemistry, Novo Nordisk A/S, Denmark


OLIGONUCLEOTIDES
OLIGONUCLEOTIDES

New Strategies and Technologies in Oligonucleotide Therapeutic Development
Thazha Prakash, Ph.D., Director, Medicinal Chemistry, Ionis Pharmaceuticals, USA

Anti-FGF2 Aptamer RBM-007 in Phase I/IIa trials for Wet AMD
Yoshikazu Nakamura, Ph.D., President and CEO, RIBOMIC Inc., and Professor Emeritus, The University of Tokyo, Japan

Emerging RNA Therapeutics: Delivery Approaches for mRNA, siRNA and Beyond
Shiro Akinaga, Ph.D., Director, Chief Scientific Officer, AccuRna Inc., Japan

Presentation Title TBA
Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals

From Stereopurity to Precision Medicine: Optimizing the Properties of Antisense Nucleic Acid Therapeutics
WAVE Lifesciences, Speaker TBA

mRNA THERAPEUTICS
mRNA THERAPEUTICS

An Introduction to mRNA Therapeutics
Jim Thompson, Ph.D., Head CMC Project Management, Moderna Therapeutics, USA

Novel mRNA Immunotherapies 
Robert Jabulowsky, Ph.D., Deputy Head of Project Management, BioNTech AG, Germany

Development of mRNA
Nigel Horscroft, D.Phil., Area Head, Molecular Therapy, CureVac AG, Germany 

Optimizing Delivery of mRNA Therapeutics
Peter Lutwyche, Ph.D., Chief Technology Officer, Genevant Sciences Corporation, Canada 

REGULATORY CONSIDERATIONS FOR OLIGOS AND PEPTIDES
REGULATORY CONSIDERATIONS FOR OLIGOS AND PEPTIDES

Regulatory Strategies for Oligonucleotides and Peptides and Updates on the Regulatory Reform at the CFDA 
Dan Zhang, M.D., Co-Founder & CEO, Fountain Medical Development, China

Regulatory Considerations on the Development of Peptide and Device Combination Products
Duu-Gong Wu, Ph.D., Senior Director, Regulatory Consulting, PPD (and Former Deputy Division Director of Division of New Drug Chemistry, CDER, FDA), USA 

Presentation TBA
David T. Lin, Ph.D., Senior Consultant, Biologics Consulting, (Former Chemistry Team Leader and Former Acting Division Director, Division of New Drug Chemistry, CDER, FDA), USA

 


NEXT GENERATION LOCKED NUCLEIC ACIDS (LNA+)
NEXT GENERATION LOCKED NUCLEIC ACIDS (LNA+)

Presentation Title TBA 
Konrad Bleicher, RNA Therapeutics, Roche Pharma Preclinical Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann-La Roche Ltd., Switzerland

Presentation Title TBA
Satoshi Inoue, Ph.D., Scientist, Bio-functional Molecular Chemistry Group, Ajinomoto Co., Inc., Japan

PEPTIDES
PEPTIDES

Genetically Encoded Selection of Novel Cyclic and Bicyclic Architectures
Ratmir Derda, Ph.D., Associate Professor, Department of Chemistry, University of Alberta, Canada

Introducing Green and Sustainable Solvents in Liquid Phase Peptide Manufacturing Processes
El Djouhar Rekaï, Ph.D., Head of Development & Manufacturing Process, PolyPeptide Group, Belgium

Peptide Quality Attributes and USP Standards
Ranjan Chakrabarti, Ph.D., Vice President & Head - Global Biologics Lab and Standards, United States Pharmacopeia, India

Cost Efficient Peptide Purification via ZEOsphere DRP Mixed-Mode Chromatography
Jurgen Machielse, Business Development Director, Zeochem AG, Switzerland

Presentation Title TBA
Daniel Samson, Ph.D., Vice President API SPPS, Bachem AG, Switzerland

PEPTIDES (Cont.)
PEPTIDES (Cont.)

Challenges in Synthesis of the Peptide API
Robert Hagopian, Director Business Development, PolyPeptide Group

Analytical methods, Pre-formulation, and Formulation for Early Phase Development
Christopher Rhodes, Ph.D., President and CEO, Drug Delivery Experts 

Toxicology and Bioanalytical Strategies/Phase 1 Strategies
Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahest

Similarities and Differences in the Product Development between a Peptide Drug and a Peptide Biologic in the US
Duu-Gong Wu, Ph.D., Senior Director, Regulatory Consulting, PPD (and Former Deputy Division Director of Division of New Drug Chemistry, CDER, FDA), USA